FIELD: medicine, pharmacology, pharmaceutical chemistry, proteins.
SUBSTANCE: invention relates to the development of agent and a method for treatment of patients with dependence from psychoactive substances. Nanomolecular selenium-terpene-protein agent represents two polypeptide α- and β-chains of protein joined by disulfide bridge by cysteine residues, selenium bonds between amino acids valine and leucine, and glutamic acids also and by two diselenide bonds between α- and β-chain. Sesquiterpene lactone (STL) is joined to selenoprotein molecule by carboxyl groups of by-side chains to residues of glutamic acid and/or aspartic acid, and/or to C-terminal carboxyl groups through ester bond in the molar ratio STL : selenoprotein = 4:1. Invention relates to a method for treatment of patients with dependence from psychoactive substances. Method involves administration of selenium-terpene-protein by the definite schedule. Nanomolecular selenium-terpene-protein agent exerts the simultaneous effect on both somatic body structures and immune system and on hypothalamus-hypophysis region, improved psychotic processes in patients by effect on energetic metabolism in nervous cells.
EFFECT: improved method for treatment, valuable medicinal properties of agent.
4 cl, 4 dwg, 2 ex
